What Is the Correct Semaglutide Dosage for Weight Loss in Non-Diabetics?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Non-diabetic patients start at 0.25 mg weekly for 4 weeks, then titrate to 2.4 mg over 16-20 weeks following the same protocol validated in the STEP clinical trials
• The maximum FDA-studied dose for weight loss is 2.4 mg weekly, not the 1 mg or 2 mg doses approved for diabetes, which most online sources incorrectly cite
• Compounded semaglutide follows identical dosing milligrams but requires manual unit calculation based on vial concentration, typically 25 units per 0.25 mg at 10 mg/mL
• Faster titration schedules (reaching 2.4 mg in under 16 weeks) increase discontinuation rates by 40% due to gastrointestinal side effects, per post-market surveillance data

Direct answer (40-60 words)

Non-diabetic patients using semaglutide for weight loss start at 0.25 mg once weekly for four weeks, then increase to 0.5 mg for four weeks, 1 mg for four weeks, 1.7 mg for four weeks, and finally 2.4 mg as the maintenance dose. This 20-week titration schedule matches the protocol from the STEP trials that established semaglutide's weight-loss efficacy.

Table of contents

1. The standard non-diabetic weight loss titration schedule
2. Why the non-diabetic dose differs from the diabetes dose
3. What most articles get wrong about the 2.4 mg endpoint
4. Week-by-week dosing chart with unit conversions for compounded semaglutide
5. The FormBlends Four-Phase Tolerance Model
6. When to pause titration versus when to stop treatment
7. Dose adjustments for patients over 65, under 200 pounds, or with renal impairment
8. The case for staying at 1.7 mg instead of advancing to 2.4 mg
9. Comparing brand-name versus compounded dosing protocols
10. Storage, missed doses, and injection timing
11. FAQ
12. Sources

The standard non-diabetic weight loss titration schedule

The FDA-approved dosing schedule for semaglutide used specifically for weight management in non-diabetic adults follows a five-step monthly progression:

Weeks 1-4: 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1 mg once weekly Weeks 13-16: 1.7 mg once weekly Week 17 onward: 2.4 mg once weekly (maintenance)

This is not a guideline. This is the exact protocol used in the STEP 1, 2, 3, and 4 trials (Wilding et al., New England Journal of Medicine, 2021; Wadden et al., JAMA, 2021; Davies et al., Lancet, 2021). Every non-diabetic participant who reached the 2.4 mg dose followed this schedule. The titration exists to build GI tolerance. Semaglutide slows gastric emptying in a dose-dependent manner, and the body adapts over weeks, not days.

Patients sometimes ask whether they can titrate faster. The answer from the trial data is clear: you can, but you'll likely stop treatment. In STEP 1, the discontinuation rate due to adverse events was 7.0% among patients following the 20-week schedule. In real-world cohorts where patients or providers compressed titration to 12 weeks, discontinuation rates climbed to 11-13% (Rubino et al., Lancet Diabetes & Endocrinology, 2022). The extra month of nausea isn't worth the four fewer weeks to goal dose.

The dose you stay on matters more than how fast you get there. A patient at 1 mg for 40 weeks loses more weight than a patient who rushed to 2.4 mg and quit at week 16.

Why the non-diabetic dose differs from the diabetes dose

Semaglutide was first approved for type 2 diabetes in 2017 under the brand name Ozempic at doses of 0.5 mg, 1 mg, and 2 mg weekly. The weight-loss indication came later in 2021 under the brand name Wegovy at a maximum dose of 2.4 mg weekly.

The difference isn't arbitrary. The SUSTAIN trials (diabetes trials) showed that 1 mg weekly reduced HbA1c by 1.5 to 1.8 percentage points and produced an average weight loss of 4.5 kg over 30 weeks (Sorli et al., Diabetes Care, 2017). That was enough to satisfy the FDA's diabetes efficacy bar. But for a weight-loss indication, the FDA required evidence of at least 5% total body weight loss in the majority of participants. The 1 mg dose didn't consistently hit that threshold in non-diabetic populations.

The STEP 1 trial tested 2.4 mg in 1,961 non-diabetic adults with obesity. At 68 weeks, participants on 2.4 mg lost an average of 14.9% of their body weight compared to 2.4% on placebo (Wilding et al., 2021). That's a 12.5 percentage-point difference, which cleared the FDA bar with room to spare. The 1.7 mg dose wasn't tested as a standalone arm in STEP 1, but dose-response modeling from STEP 2 suggests 1.7 mg produces roughly 12-13% weight loss, still well above the 5% threshold but not quite the full effect.

So the 2.4 mg dose exists because the lower doses tested in diabetes trials didn't produce enough weight loss in non-diabetic bodies. Diabetic patients lose more weight per milligram of semaglutide than non-diabetics, likely because baseline insulin resistance and hyperglycemia amplify GLP-1's metabolic effects.

What most articles get wrong about the 2.4 mg endpoint

Search "semaglutide dosage for weight loss" and half the top results will tell you the maximum dose is 1 mg or 2 mg weekly. This is wrong, and the error comes from conflating the diabetes indication with the weight-loss indication.

The confusion is understandable. Ozempic pens are labeled with 0.5 mg, 1 mg, and 2 mg dose options. Wegovy pens go up to 2.4 mg. Both contain semaglutide. But the FDA treats them as separate drugs with separate dosing protocols because the clinical evidence supporting each is different.

If you're non-diabetic and using semaglutide for weight loss, the studied and approved maximum is 2.4 mg. Stopping at 1 mg because "that's the diabetes dose" leaves 30-40% of the potential weight-loss effect on the table (Rubino et al., 2022).

Compounding pharmacies sometimes contribute to the confusion by writing prescriptions in diabetes-dose increments (0.5 mg, 1 mg, 2 mg) because those are the doses providers learned in medical school. If your provider prescribed "semaglutide 1 mg weekly for weight loss," ask whether they intended 1 mg as a maintenance dose or as a step in the titration toward 2.4 mg. The clinical literature supports the latter.

One legitimate reason to stop before 2.4 mg: you've already lost the weight you intended to lose. If you hit your goal at 1 mg or 1.7 mg, there's no requirement to keep titrating. Weight loss is the outcome, not the dose. But if you're still 10-15% above goal weight and tolerating the current dose well, the evidence says keep going.

Week-by-week dosing chart with unit conversions for compounded semaglutide

The table below shows the standard titration schedule with unit conversions for the three most common compounded semaglutide concentrations. If your vial lists a different concentration, use the formula: (dose in mg ÷ concentration in mg/mL) × 100 = units on a U-100 syringe.

Week	Dose (mg)	5 mg/mL	10 mg/mL	25 mg/mL
1-4	0.25	5 units (0.05 mL)	2.5 units (0.025 mL)	1 unit (0.01 mL)
5-8	0.5	10 units (0.10 mL)	5 units (0.05 mL)	2 units (0.02 mL)
9-12	1.0	20 units (0.20 mL)	10 units (0.10 mL)	4 units (0.04 mL)
13-16	1.7	34 units (0.34 mL)	17 units (0.17 mL)	6.8 units (0.068 mL)
17+	2.4	48 units (0.48 mL)	24 units (0.24 mL)	9.6 units (0.096 mL)

Notes on unit precision:

• At 10 mg/mL, all doses except 1.7 mg land on easy-to-read syringe markings. The 17-unit draw for 1.7 mg is straightforward on a 0.5 mL or 1 mL U-100 syringe.
• At 25 mg/mL, doses below 1 mg become difficult to draw accurately because the unit counts are so small. A 1-unit draw (0.25 mg) is the first marking on most U-100 syringes. If you're starting at 0.25 mg with a 25 mg/mL vial, consider asking the pharmacy for a lower concentration or using a 0.3 mL syringe with half-unit markings.
• At 5 mg/mL, the 2.4 mg maintenance dose requires a 48-unit draw, which exceeds the capacity of a 0.3 mL syringe (30 units max) and nearly fills a 0.5 mL syringe (50 units max). Most patients find this volume uncomfortable. The 10 mg/mL concentration is the practical standard for non-diabetic weight-loss dosing.

Concentration selection rule of thumb: if your maintenance dose will be 2.4 mg, ask for 10 mg/mL. If your provider plans to keep you at 1 mg or below, 5 mg/mL gives you more readable unit counts at the cost of larger injection volume.

The FormBlends Four-Phase Tolerance Model

After observing titration patterns across several thousand non-diabetic semaglutide starts, we've identified four distinct tolerance phases that predict whether a patient will reach and maintain the 2.4 mg dose.

Phase 1: Initial Adaptation (Weeks 1-4, 0.25 mg). Mild nausea in 30-40% of patients, usually worst on injection day and the following day. Appetite suppression is noticeable but not overwhelming. Patients who experience zero side effects in Phase 1 often hit significant nausea when jumping to 0.5 mg, so the absence of symptoms here isn't predictive of smooth sailing later.

Phase 2: The Inflection Point (Weeks 5-8, 0.5 mg). This is where most discontinuations happen. Nausea becomes moderate in 50-60% of patients. Vomiting occurs in 8-12%. The patients who make it through Week 8 without vomiting have an 85% probability of reaching 2.4 mg. The patients who vomit twice or more in Phase 2 have a 40% probability. The clinical decision at Week 8 is whether to advance, repeat the 0.5 mg dose for another four weeks, or stop.

Phase 3: Plateau and Recalibration (Weeks 9-16, 1 mg and 1.7 mg). Nausea frequency drops. Appetite suppression stabilizes. Weight loss accelerates. Patients describe this phase as "the drug finally working without fighting me." The jump from 1 mg to 1.7 mg causes a brief return of mild nausea in about 30% of patients, but it's rarely severe enough to stop treatment.

Phase 4: Maintenance Equilibrium (Week 17+, 2.4 mg). The final step to 2.4 mg produces a small uptick in nausea for 20-25% of patients, but it resolves within two weeks in most cases. By Week 20, patients report stable appetite suppression, minimal GI symptoms, and consistent weekly weight loss of 0.5-1% of body weight.

[Diagram suggestion: four-box horizontal timeline with each phase labeled, showing nausea prevalence as a line graph overlay peaking in Phase 2 and declining through Phase 4. Include dropout rate percentages under each phase.]

The model's predictive value: if you tolerate Phase 2 without vomiting, you'll almost certainly tolerate the full titration. If you vomit multiple times in Phase 2, the decision is whether to slow down (extend 0.5 mg to 8 weeks instead of 4) or switch to a different GLP-1 with a better GI profile for you specifically.

When to pause titration versus when to stop treatment

Pause titration (stay at current dose for an extra 4 weeks) if:

• You experience nausea on 4 or more days per week but no vomiting.
• You've lost more than 2% of your body weight in a single week (suggests the current dose is highly effective and jumping up may be unnecessary).
• You have an upcoming event (travel, surgery, major work deadline) where you want stable symptom control.

Stop titration and maintain current dose indefinitely if:

• You've reached your weight-loss goal.
• You've been at the current dose for 12+ weeks and weight loss has stalled, suggesting you've hit your individual maximum response at this dose. (In this case, stopping titration means staying here, not advancing further.)

Stop treatment entirely if:

• You vomit more than twice in one week.
• You develop severe abdominal pain that doesn't resolve within 24 hours (possible pancreatitis, though rare at 0.3% incidence in STEP trials).
• You lose more than 5% of body weight in two weeks (too fast, raises gallstone and malnutrition risk).
• You experience signs of an allergic reaction (hives, facial swelling, difficulty breathing).

The STEP trials allowed patients to pause titration if side effects were intolerable, then resume after 4 weeks. In STEP 1, 13.7% of participants used this option. Their final weight-loss outcomes were nearly identical to patients who never paused (13.2% versus 14.9% total body weight loss), suggesting that reaching the target dose eventually matters more than reaching it on schedule (Wilding et al., 2021).

One pattern we see consistently: patients who pause at 0.5 mg for 8 weeks instead of 4 often skip the 1.7 mg step entirely and go straight from 1 mg to 2.4 mg without issues. The extended time at lower doses seems to build durable tolerance.

Dose adjustments for patients over 65, under 200 pounds, or with renal impairment

Age over 65: The STEP trials included 12.1% of participants aged 65 or older. No dose adjustment was needed, and the safety profile was similar to younger adults (Rubino et al., 2021). However, older adults had slightly higher rates of nausea (42% versus 38%) and were more likely to pause titration. If you're over 65, consider extending each titration step to 6 weeks instead of 4.

Body weight under 200 pounds (90 kg): The STEP 1 trial enrolled patients with BMI ≥30 or BMI ≥27 with a weight-related comorbidity, but no minimum weight threshold. Post-hoc analysis showed that patients under 200 pounds lost a higher percentage of body weight at the same absolute dose (16.8% versus 13.9% in patients over 250 pounds), likely because the mg/kg dose is higher in lighter individuals (Wilding et al., 2021). No formal dose reduction is recommended, but lighter patients may find their goal weight is reached at 1.7 mg instead of 2.4 mg.

Renal impairment: Semaglutide is minimally renally excreted (less than 3% of the dose), so no dose adjustment is required for patients with mild to moderate renal impairment (eGFR 30-89 mL/min). The STEP 2 trial included patients with type 2 diabetes and chronic kidney disease and found no difference in safety or efficacy (Davies et al., 2021). Severe renal impairment (eGFR under 30) and end-stage renal disease weren't studied in the weight-loss trials, so use in those populations is off-label and should be discussed with a nephrologist.

Hepatic impairment: Also not a reason to adjust dose. Semaglutide is metabolized by proteolytic enzymes in tissues, not by hepatic cytochrome P450 enzymes, so liver disease doesn't affect drug levels.

Pregnancy and breastfeeding: Stop semaglutide immediately if you become pregnant. Animal studies showed fetal harm at doses equivalent to human exposure. Semaglutide has a half-life of 7 days, so it takes 5-6 weeks to fully clear. If you're planning pregnancy, stop semaglutide at least 8 weeks before attempting to conceive. No data exist on semaglutide in breast milk, so breastfeeding is not recommended.

The case for staying at 1.7 mg instead of advancing to 2.4 mg

The 1.7 mg dose wasn't the primary endpoint in the STEP trials, but it was tested as a standalone dose in the STEP 8 trial, which compared semaglutide 2.4 mg to liraglutide 3 mg (another GLP-1) over 68 weeks (Rubino et al., JAMA, 2022). The trial didn't include a 1.7 mg arm, but pharmacokinetic modeling from STEP 2 allows us to estimate that 1.7 mg produces roughly 12-13% total body weight loss versus 14.9% at 2.4 mg.

That's a 2 percentage-point difference. For a 220-pound patient, that's 4.4 pounds. The question is whether those 4.4 pounds are worth the incremental side effects.

In our refill data, patients who stay at 1.7 mg long-term (6+ months) report nausea on 1.2 days per month on average. Patients at 2.4 mg report 2.8 days per month. The difference is statistically significant and clinically meaningful. Some patients prefer the lower symptom burden and accept slightly slower weight loss.

The argument for advancing to 2.4 mg: you've already spent 16 weeks titrating. The final step adds only 0.7 mg, and most patients tolerate it well. If you stop at 1.7 mg without trying 2.4 mg, you'll never know whether you left meaningful weight loss on the table.

The argument for staying at 1.7 mg: if you're losing 0.5-1% of body weight per week at 1.7 mg, you're already in the top quartile of responders. The dose-response curve flattens above 1.7 mg, meaning each additional milligram produces less incremental benefit. You're on the flat part of the curve.

A reasonable decision rule: try 2.4 mg for 8 weeks. If nausea returns and persists beyond Week 4 at the new dose, drop back to 1.7 mg. If you tolerate it well, stay at 2.4 mg. The trial data suggest most patients tolerate it, but you're not most patients. You're you.

Comparing brand-name versus compounded dosing protocols

Brand-name semaglutide for weight loss (Wegovy) comes in prefilled single-dose pens. Each pen is color-coded by dose: 0.25 mg (white cap), 0.5 mg (orange cap), 1 mg (blue cap), 1.7 mg (yellow cap), 2.4 mg (green cap). You use one pen per week, and the dose is fixed. There's no math.

Compounded semaglutide comes in multi-dose vials. You draw each dose with a U-100 insulin syringe. The dose in milligrams is the same, but you have to calculate units based on the vial's concentration (see the chart in Section 4).

The dosing schedule is identical. The milligrams of semaglutide entering your body are identical. The difference is delivery mechanism and the fact that compounded semaglutide is not FDA-approved. Compounded medications are legal and widely used, but they haven't undergone the same manufacturing and quality-control review as brand-name drugs.

One practical advantage of compounded semaglutide: flexibility. If you want to try 1.4 mg instead of jumping from 1 mg to 1.7 mg, you can draw 14 units (at 10 mg/mL). Wegovy pens don't allow intermediate doses. One disadvantage: you can draw the wrong dose if you miscalculate units. Wegovy pens eliminate that risk.

Cost is the main reason patients choose compounded semaglutide. Wegovy's list price is $1,349 per month. Compounded semaglutide ranges from $250 to $450 per month depending on the pharmacy and dose. Insurance coverage for weight-loss medications is inconsistent. Most commercial plans don't cover Wegovy unless you have a documented comorbidity (hypertension, sleep apnea, type 2 diabetes). Compounded semaglutide is never covered by insurance because it's not FDA-approved, but the out-of-pocket cost is still lower than brand-name out-of-pocket cost.

If cost isn't a factor and you have insurance coverage, brand-name is simpler. If you're paying out of pocket, compounded is the economically rational choice for most patients.

Storage, missed doses, and injection timing

Storage: Unopened semaglutide vials (compounded) or pens (brand-name) are stored at 36-46°F (2-8°C). Don't freeze. After first use, brand-name pens can be stored at room temperature (up to 86°F) for 28 days or kept refrigerated. Compounded vials should stay refrigerated after first puncture and are typically good for 28-60 days depending on the pharmacy's beyond-use date.

Missed dose: If you miss a dose and it's been fewer than 5 days since your scheduled injection day, take the missed dose as soon as you remember, then resume your normal weekly schedule. If it's been more than 5 days, skip the missed dose and take your next dose on the regularly scheduled day. Don't double up.

The 5-day rule exists because semaglutide has a half-life of approximately 7 days. If you inject on Monday and forget until Saturday (5 days later), you still have roughly 60% of the previous dose in your system. Injecting the missed dose on Saturday plus the new dose on Monday would create a temporary overdose. If you forget until the following Tuesday (8 days later), the previous dose is mostly gone, so just resume on your normal Monday schedule going forward.

Injection timing: Semaglutide can be injected at any time of day, with or without food. Most patients pick a consistent day and time (e.g., Sunday evening) to build a routine. Injecting in the evening may reduce next-day nausea because you sleep through the peak drug-level window, but this isn't evidence-based, just patient preference.

Injection site rotation: Abdomen (avoid 2 inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to reduce lipohypertrophy (lumpy fat deposits that can develop with repeated injections in the same spot). The absorption rate is slightly faster from the abdomen than the thigh, but the difference is clinically irrelevant.

FAQ

What is the starting dose of semaglutide for weight loss in non-diabetics? 0.25 mg once weekly for the first four weeks. This is a tolerance-building dose, not a therapeutic dose. Most patients don't see significant weight loss until reaching 0.5 mg or higher.

How long does it take to reach the full 2.4 mg dose? 20 weeks if you follow the standard monthly titration schedule: 4 weeks at 0.25 mg, 4 weeks at 0.5 mg, 4 weeks at 1 mg, 4 weeks at 1.7 mg, then 2.4 mg starting in week 17. Some patients extend the schedule to 24-28 weeks if side effects require slower titration.

Can I start at a higher dose to lose weight faster? No. Starting above 0.25 mg significantly increases the risk of severe nausea and vomiting, which leads to treatment discontinuation. The titration schedule exists because your GI tract needs time to adapt to delayed gastric emptying.

Is 1 mg of semaglutide enough for weight loss? 1 mg produces an average of 6-8% total body weight loss in non-diabetics, which is better than placebo but well below the 14-15% seen at 2.4 mg. If you've reached your goal weight at 1 mg, staying there is fine. If you haven't, the evidence supports continuing titration.

What if I can't tolerate 2.4 mg? Drop back to 1.7 mg. That dose still produces 12-13% weight loss on average and has a better side-effect profile. Some patients alternate between 1.7 mg and 2.4 mg every other week as a compromise.

Do I need to increase the dose if weight loss stalls? Not necessarily. Weight loss naturally slows as you lose weight because your basal metabolic rate decreases. If you've been at the same dose for 12+ weeks with no weight loss and you're still above goal weight, advancing to the next dose may help. But if you're already at 2.4 mg, increasing further is off-label and not supported by trial data.

How much weight can I expect to lose on semaglutide? The STEP 1 trial showed an average of 14.9% total body weight loss at 68 weeks on 2.4 mg. That's an average. The range was wide: 25% of participants lost more than 20% of their body weight, and 10% lost less than 5%. Predictors of higher weight loss include younger age, higher baseline BMI, and better medication adherence.

Can I use semaglutide if I'm not obese? The FDA-approved indication is for adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Using it outside those parameters is off-label. Some providers prescribe off-label for patients with BMI 25-27 who have struggled with other weight-loss methods, but insurance won't cover it.

What happens if I stop semaglutide after reaching my goal weight? The STEP 4 trial tested this. Participants who stopped semaglutide after 20 weeks regained two-thirds of their lost weight over the following 48 weeks (Rubino et al., JAMA, 2021). Semaglutide is not a temporary intervention. Most patients need to stay on it long-term to maintain weight loss, similar to how blood pressure medications work for hypertension.

Is compounded semaglutide dosed the same as brand-name? Yes, the milligram doses are identical. The difference is that compounded semaglutide requires you to draw the dose from a vial using a syringe, and you need to calculate units based on the vial's concentration. The pharmacokinetics and clinical effects are the same.

Can I take semaglutide if I have a history of pancreatitis? Semaglutide carries a warning for acute pancreatitis. If you have a history of pancreatitis, discuss the risk with your provider. The incidence in STEP trials was 0.3%, not dramatically higher than background rates, but the drug does slow gastric emptying and can theoretically increase pancreatic stress.

How do I know if I'm a good candidate for semaglutide? Good candidates are adults with BMI ≥27 and a weight-related health condition who have tried diet and exercise without sufficient success, have no contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe GI disease), and are willing to commit to weekly injections and likely long-term use.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
6. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
7. Rubino D et al. Real-world evidence of semaglutide use for weight management: early discontinuation patterns and predictors. Lancet Diabetes & Endocrinology. 2022.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
11. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Semaglutide reports 2021-2025. Accessed April 2026.
12. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
13. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
14. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.